UroToday

1 month ago | urotoday.com | Mark Tyson

Read the Full Video TranscriptSam Chang: Hi, I'm Sam Chang. I'm a urologist in Nashville, Tennessee, at Vanderbilt University Medical Center. And we have Dr. Mark Tyson, a professor at Mayo Scottsdale. And Dr. Tyson obviously doesn't really need an introduction. Really one of the stars in bladder cancer and actually all of urologic oncology. Dr. Tyson actually presented an important work in the P2 program in the AUA 2025 that focuses on practice changing and paradigm shifting work.

2 months ago | urotoday.com | Matthias Benz

Read the Full Video TranscriptMatthias Benz: Here we go. Good morning, everybody. Just following on Amir's talk. I have a relatively basic talk. Nothing to disclose. A pretty broad topic, this topic, but I just narrowed it down to two things. I want to show a few false positive findings that also kind of follows what Amir says—that residency, radiology residency, and a good program that you're kind of attending is important.

2 months ago | urotoday.com | Adam P. Dicker

Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here today, talking with Dr. Adam Dicker at GU ASCO 2025. He's joining me from Thomas Jefferson University. Thank you so much for being here. Adam P. Dicker: My pleasure. Alicia Morgans: Wonderful. So there's been a lot of excitement about MMAI, this artificial intelligence that helps us really understand pathology specimens on a deeper level, maybe being prognostic or predictive of certain outcomes for patients.

Feb 20, 2025 | urotoday.com | Mark Tyson

Read the Full Video TranscriptAshish Kamat: Hello everyone, and welcome to UroToday. I'm Ashish Kamat, Professor of Urologic Oncology at M.D. Anderson Cancer Center, and it's a pleasure to welcome to the forum once again someone who's been with us many times, Professor Mark Tyson from Phoenix, Arizona, and also his mentee, a pre-med student, Jacob Moyer. So welcome to the forum, guys. Mark Tyson: Thank you, Dr. Kamat. Pleasure to be here. Jacob Moyer: Great to be here. Thanks for having us.

Feb 18, 2025 | urotoday.com | Laura Sena

Read the Full Video TranscriptAndrea Miyahira: Hi, everyone. I'm Andrea Miyahira at the Prostate Cancer Foundation. I'm pleased to welcome Dr. Laura Sena from Johns Hopkins University, who will discuss her recent paper, "Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer," published in NPJ Precision Oncology. Dr. Sena, thank you for coming on today. Laura Sena: Thanks so much for having me, Andrea.